Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise
November 24, 2025
Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep FranchiseNovember 24, 2025 Eversheds Sutherland is pleased to have advised Azurity Pharmaceuticals on its acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies. The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States. With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams. Read Azurity’s press release here. The Eversheds Sutherland team was led by Partner Mike Voynich (Corporate), with support from Partner Pete Pappas (Intellectual Property), Special Counsel Anna Halsey (Intellectual Property), Senior Associate Adam Byrne (Corporate) and Associate Haley Klass (Corporate). Key contacts
Latest Insights
Latest News
Latest Events
client news June 02, 2026 Next stop, public ownership: Eversheds Sutherland advises DfT on GTR transi... firm news June 01, 2026 Shaping the Future firm news June 01, 2026 Eversheds Sutherland strengthens restructuring offering with senior partner... firm news June 01, 2026 Eversheds Sutherland strengthens Commercial Advisory practice with technolo... virtual UK employment law training June 09, 2026 1pm - 4pm (BST) Virtual virtual Nordic (Denmark, Finland, Norway and Sweden) employment law training June 16, 2026 12.45pm - 4pm (BST) Virtual virtual Webinar: Conquering the US Market June 23, 2026 17.00-18.00 virtual Introduction to Swiss employment law June 23, 2026 2pm - 5pm (GMT) Virtual |